Here's the Surprising Amount of Money Pfizer's Vaccine Might Make Immunizing Adolescents

Pfizer (NYSE: PFE) has racked up multiple firsts with its vaccine. BNT162b2 was the first COVID-19 vaccine to win Emergency Use Authorization (EUA) in the U.S. for adults. It was the first to win EUA for teens ages 16 and up. And now another first could be on the way.

A couple of weeks ago, Pfizer and its partner BioNTech (NASDAQ: BNTX) reported results from a late-stage study of BNT162b2 in children ages 12 to 15. BNT162b2 achieved an efficacy of 100% in the study. The companies announced on April 9 that they've filed for an expanded EUA for this lower age group with the U.S. Food and Drug Administration (FDA).

Pfizer previously estimated that BNT162b2 would generate sales of around $15 billion this year. However, that figure was based on the supply deals it had in place in early February. How much money could Pfizer make in 2021 if it wins authorization for the vaccine in adolescents? You might be surprised.

Source Fool.com